Syncromune® Showcases Early SYNC-T™ SV-102 Trial Data at AACR 2024

A significant medical presentation is scheduled to occur at the San Diego Convention Center from 3:00 to 5:00 PM PT, as part of the "Cancer Vaccines: Ready for Prime Time?" session. The clinical-stage biopharmaceutical firm, Syncromune®, Inc., will showcase groundbreaking data from their Phase 1 clinical trials of SYNC-T, a pioneering in situ platform therapy tailored for solid tumor cancers, at the AACR Annual Meeting 2024.
Dr. Charles J. Link, M.D., will present findings from the SV-102 Phase 1 trial, highlighting the systemic responses to SYNC-T therapy, which involves the in situ personalized cancer vaccination with intratumoral infusion of multitarget immunotherapy in patients with metastatic castrate-resistant prostate cancer (mCRPC). This marks the inaugural public disclosure of SYNC-T therapy platform data from the company's clinical trials.
Syncromune®, a privately owned entity, is focused on developing an in situ platform technology for metastatic solid tumor cancers, with a vision to enhance survival rates and achieve higher response rates. Their flagship product, SYNC-T™, is a novel combination drug/device therapy platform designed to synchronize in situ neoantigen T cell education and immunostimulation via intratumoral infusion. This approach aims to empower the immune system to identify and combat cancer systemically. The company's first two candidates, SV-101 and SV-102, are currently undergoing Phase 1 trials.
SYNC-T™ is an innovative platform that employs a dual strategy of in situ vaccination through device-induced cryolysis and the intratumoral infusion of a multi-target biologic drug. The goal is to synchronize the timing and location of tumor antigen release with the activation of immune cells, thereby activating the immune system against immune suppression and enabling patient-specific T cell education. This can lead to the expansion of anti-cancer T cells, which can recognize and eradicate cancer in both treated tumors and distant metastases.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!